Skip to NavigationSkip to content

Amgen's novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours

Published on 04/06/19 at 10:42am

Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach clinical stage, at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, investigating its efficacy as a monotherapy in patients with locally-advanced or metastatic KRASG12C mutant solid tumours.

The trial examined the drug’s use in 35 participants, 14 with non-small cell lung cancer (NSCLC), 19 with colorectal cancer (CRC) and two others, with all eligible patients previously treated with at least two lines of treatment according to their tumour type and disease stage.

The study findings revealed that five of the ten NSCLC achieved a partial response (PR) another four achieved stable disease (SD), representing a 90% disease control rate and with one patient progressing to complete response at week 18.

In the 18 CRC patients, 13 achieved SD. Twenty-six patients will continue to be studied while nine had discontinued treatment.

"KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago, but it remained undruggable due to a lack of traditional small molecule binding pockets on the protein. AMG 510 seeks to crack the KRAS code by exploiting a previously hidden groove on the protein surface," commented Dr David M Reese, Executive Vice President of Research and Development at Amgen. "By irreversibly binding to cysteine 12 on the mutated KRAS protein, AMG 510 is designed to lock it into an inactive state. With high selectivity for KRAS, we believe investigational AMG 510 has high potential as both a monotherapy and in combination with other targeted and immune therapies."

Dr Marwan G Fakih, Clinical Study Investigator and co-Director of the Gastrointestinal Cancer Program in California, added: "While there's been significant progress in treating solid tumor cancers overall with targeted therapies, patients with the KRAS mutation have not benefited from these advances. In this early Phase 1 trial, investigational AMG 510 showed encouraging anti-tumor activity. We look forward to further investigating AMG 510 with the goal of closing the treatment gap for patients with this type of mutation."

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches